CADL
Candel Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
CADL Profile
Candel Therapeutics, Inc.
A late clinical stage biopharmaceutical company that develops novel oncolytic viral immunotherapies
Biological Technology
Invalid Date
07/27/2021
NASDAQ Stock Exchange
38
12-31
Common stock
117 Kendrick St Suite 450, Needham, MA 02494
--
Candel Therapeutics, Inc., was incorporated in Delaware in June 2003. The company is a clinical-stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that trigger individualized, systemic anti-tumor immune responses to help patients fight cancer.